Home > Cardiology > ACC/WCC 2020 > Vascular Medicine and Thromboembolism > Bleeding reduction post-TAVI with OAC alone vs OAC + clopidogrel

Bleeding reduction post-TAVI with OAC alone vs OAC + clopidogrel

Presented By
Dr V. Nijenhuis, St. Antonius Hospital, the Netherlands
ACC 2020
In patients with an established indication for oral anticoagulation (OAC) undergoing transcatheter aortic valve implantation (TAVI), OAC alone as compared with OAC + clopidogrel reduced the rate of bleeding events, including major life-threatening bleeding events, without increasing the rate of thrombotic events [1,2]. The POPular TAVI trial is an investigator-initiated, randomised, open-label trial conducted in 17 centres in Europe. The purpose of this trial was to investigate whether extra antithrombotic protection post-TAVI was coupled with extra safety issues. Dr Vincent Nijenhuis (St. Antonius Hospital, the Netherlands) presented the results for 1 of the 2 study cohorts. This cohort consists of patients who were undergoing TAVI and had an established indication for long-term OAC. Patients were randomised to receive clopidogrel on top of their existi...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on